A real-world disproportionality analysis of Rucaparib: Post-marketing Pharmacovigilance Data

A real-world disproportionality analysis of Rucaparib: Post-marketing Pharmacovigilance Data

Abstract Background Rucaparib has been approved for the maintenance treatment of adult patients with recurrent epithelial ovarian, fallopian tube, or primary peritoneal cancer. However, the long-term safety of rucaparib in large sample population was unknown. The presented study aimed to evaluate ru...

Full description

Bibliographic Details
Main Authors: Qilin Zhang, Yiling Ding, Yamin Shu, Jing Chen
Format: Article
Language:English
Published: BMC 2023-08-01
Series:BMC Cancer
Subjects:
Adverse event
Data mining
Disproportionality analysis
FAERS
Pharmacovigilance
Rucaparib
Online Access:https://doi.org/10.1186/s12885-023-11201-w

Internet

https://doi.org/10.1186/s12885-023-11201-w

Similar Items